Navigation Links
De nouvelles directives recommandent la fidaxomicine pour tous les patients pouvant suivre un traitement antibiotique par voie orale pour une infection à Clostridium difficile
Date:10/29/2013

est une étape importante pour la réduction de la morbidité et de la mortalité associée à l'ICD », déclare le professeur Oliver Cornely de l'hôpital universitaire de Cologne en Allemagne. « J'approuve ces directives et je pense que l'application de ces recommandations améliorera le traitement de l'ICD et réduira le fardeau à la fois pour les patients et les systèmes de santé. »

Deux importantes études cliniques de phase III comparant l'efficacité et l'innocuité de 400 mg par jour fidaxomicine par voie orale à 500 mg par jour de vancomycine ont permis de montrer les avantages potentiels de la fidaxomicine par rapport à la vancomycine qui est le traitement habituel.[9],[11] Les patients participant à ces essais présentaient un diagnostic confirmé d'ICD et incluaient des patients classés comme souffrant d'une ICD grave ainsi que des patients pour lesquels l'ICD constituait un risque particulièrement important comme les personnes âgées[11] ou avec des pathologies concomitantes.[12],[13],[14] La fidaxomincine a permis de réduire considérablement le taux de récurrence de l'ICD comparé à la vancomycine et les patients traités avec la fidaxomicine étaient plus susceptibles de ne plus souffrir de diarrhées sans récurrence 30 jours après la fin du traitement, que les patients traités avec de la vancomycine.[9],[11] La fidaxomicine a également atteint son critère d'évaluation principal de taux de guérison clinique qui était équivalent à celui de la vancomycine.[9],[11]

Certaines populations courent un risque plus élevé d'ICD et sont particulièrement vulnérables. L'ICD peut être as
'/>"/>

SOURCE Astellas Pharma Europe Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Medicare Procurement Program Creates Extreme Hardships For North Carolina Patients, Says AAHomecare
2. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
3. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
4. 3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
5. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
6. Medicare Procurement Program Creates Extreme Hardships for Patients without Options, Says AAHomecare
7. Media Sourcerys Secure Mobile Workflow App Deployed by CCS Medical to Expedite Product Delivery to Patients
8. Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States
9. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
10. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
11. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
(Date:7/30/2015)... 30, 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... and webcast at 5:00 p.m. Eastern Time (2:00 p.m. ... second quarter 2015 financial results and provide a corporate ... NASDAQ Global Select Market closes that day. ... for domestic callers and 914.495.8552 for international callers. Please ...
(Date:7/30/2015)... , July 30, 2015 EnteroMedics Inc. (NASDAQ: ... neuroblocking technology to treat obesity, metabolic diseases and other ... conference call on Thursday, August 6, 2015, at 11:00 ... second quarter ended June 30, 2015, and to provide ... Neurometabolic Therapy, delivered via the Maestro® System. ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3
... May 18 AccuVein LLC today announced it had signed ... sell the AV300 vein finder in India . With ... , , ... veins for blood draw , IV infusion and blood ...
... SAN FRANCISCO , May 18 Teva ... treated with a standard or low dose of ENJUVIA® (synthetic ... often they were awakened at night by hot flashes compared ... at the 58th Annual Clinical Meeting of the American College ...
Cached Medicine Technology:AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device 2AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device 3New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 2New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 3New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 4New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 5New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 6New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 7
(Date:7/30/2015)... ... ... Ross A. Clevens, MD, FACS has been reappointed by the University ... This is Dr. Clevens’ second appointment by the prestigious school. Over the past ... and a valuable mentoring program for medical students. , The University ...
(Date:7/30/2015)... Beach, California (PRWEB) , ... July 30, 2015 ... ... and services, announced today that the latest issue of Inclusive™ magazine, its multimedia ... digital platforms. The digital edition of the new issue, Volume 6, Issue 2, ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Partners All-Star at the annual All-Stars Summit. Google Partners is the platform for ... may receive the full support and tools necessary to run successful search marketing ...
(Date:7/30/2015)... , ... July 30, 2015 , ... Quintessa Medical Spa ... is a nonsurgical treatment designed specifically for the elimination of excess tissue ... the first locations in the state of Wisconsin to offer this innovative treatment. , ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... Administration (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription ... Saturday, September 26, 2015 from 10:00 AM to 2:00 PM local time. On ...
Breaking Medicine News(10 mins):Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3
... NY (March 3, 2009) A study published in the ... (AJN) found that almost 40% of nurses who were on ... misconduct between 2001 and 2005. Nurses on probation who ... recidivate, suggesting that licensing boards should carefully screen and monitor ...
... this country. Many employers don,t want to hire them, and ... their own communities and families, the mentally ill are often ... efforts to combat the stigma of mental illness, but with ... are so powerful: Mental patients are either violently dangerous or ...
... March 3 /PRNewswire-USNewswire/ - - The following ... Action Network, American Heart Association, American Lung Association ... strongly support the bipartisan legislation introduced today to ... with effective authority to regulate tobacco products. ...
... undamaged areas to compensate, study finds , , TUESDAY, March ... to start losing his or her sight, the affected ... parts of the eye, Massachusetts Institute of Technology researchers ... the brain changes when its inputs change. Neurons seem ...
... 3 Tyco International Ltd. (NYSE: TYC ; ... a Special General Meeting of shareholders on March 12, 2009 ... The Annual General Meeting will begin at 9:00 a.m. ... Meeting at 9:30 a.m. Atlantic Time. During the meetings, ...
... Center is participating in a National Institutes of Health ... to reduce the risk of stroke patients suffering another ... stroke victims for high blood pressure and cholesterol, along ... in a patient,s brain, is better than intensive medical ...
Cached Medicine News:Health News:New research in AJN shows link between nurse's criminal history and professional misconduct 2Health News:New research in AJN shows link between nurse's criminal history and professional misconduct 3Health News:His and hers: Study examines the role of gender in the stigma of mental illness 2Health News:Congress Can Deliver Historic Victory for Children and America's Health By Granting FDA Authority Over Tobacco Products 2Health News:Congress Can Deliver Historic Victory for Children and America's Health By Granting FDA Authority Over Tobacco Products 3Health News:Brain Adapts to Age-Related Eye Disease 2Health News:Tyco to Host 2009 Annual General Meeting and Special General Meeting of Shareholders 2Health News:Preventing a second stroke is focus of study at Rush University Medical Center 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: